328 related articles for article (PubMed ID: 20030613)
1. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
Steffen I; Pöhlmann S
Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
3. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
6. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
7. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
9. HIV entry and fusion inhibitors.
Chantry D
Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
Gustchina E; Louis JM; Bewley CA; Clore GM
J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381
[TBL] [Abstract][Full Text] [Related]
11. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
13. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
14. The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection.
Tan JJ; Ma XT; Liu C; Zhang XY; Wang CX
Curr Pharm Des; 2013; 19(10):1810-7. PubMed ID: 23092283
[TBL] [Abstract][Full Text] [Related]
15. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
Gómara MJ; Haro I
Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
[TBL] [Abstract][Full Text] [Related]
16. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
17. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
[TBL] [Abstract][Full Text] [Related]
18. HIV fusion inhibitors.
Qadir MI; Malik SA
Rev Med Virol; 2010 Jan; 20(1):23-33. PubMed ID: 19827030
[TBL] [Abstract][Full Text] [Related]
19. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
20. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]